FY2017 EPS Estimates for Aurinia Pharmaceuticals Inc Lifted by Cantor Fitzgerald (AUPH)
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) – Cantor Fitzgerald boosted their FY2017 earnings per share estimates for shares of Aurinia Pharmaceuticals in a report released on Wednesday. Cantor Fitzgerald analyst E. Piros now anticipates that the biotechnology company will earn ($1.01) per share for the year, up from their previous estimate of ($1.15). Cantor Fitzgerald currently has a “Buy” rating and a $14.00 target price on the stock. Cantor Fitzgerald also issued estimates for Aurinia Pharmaceuticals’ FY2018 earnings at ($0.72) EPS.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.10. The company had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $0.06 million. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%.
Other analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. BidaskClub downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. HC Wainwright dropped their target price on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, May 18th. Finally, Vetr downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.72 target price for the company. in a research report on Monday, August 14th. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. Aurinia Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $9.72.
Shares of Aurinia Pharmaceuticals (AUPH) opened at 6.06 on Monday. Aurinia Pharmaceuticals has a 52-week low of $1.88 and a 52-week high of $10.54. The stock’s market capitalization is $505.92 million. The firm has a 50-day moving average of $6.28 and a 200 day moving average of $6.37.
A number of hedge funds have recently modified their holdings of AUPH. Royal Bank of Canada increased its stake in shares of Aurinia Pharmaceuticals by 8.6% in the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 1,341 shares during the period. Jane Street Group LLC bought a new stake in Aurinia Pharmaceuticals during the first quarter worth $155,000. Cutler Capital Management LLC bought a new stake in Aurinia Pharmaceuticals during the second quarter worth $184,000. Investment Centers of America Inc. bought a new stake in Aurinia Pharmaceuticals during the second quarter worth $184,000. Finally, Two Sigma Securities LLC bought a new stake in Aurinia Pharmaceuticals during the first quarter worth $240,000. 27.83% of the stock is owned by institutional investors.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.